Oseltamivir
Pharmaceutical forms
Capsule
Country lists
ATC N/A
Composition 30 mg (as phosphate)
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.3. Other antivirals
  • Others observations:
    Oseltamivir should be used only in compliance with the WHO treatment guidelines, i.e. (1) for treatment of patients with severe or progressive clinical illness with confirmed or suspected influenza pandemic (H1N1) 2009, (2) for the treatment of patients with confirmed or suspected but uncomplicated illness due to pandemic influenza virus infection who were in higher risk groups, most notably for pregnant women and children under 2 years of age.
Tablet
Country lists
ATC N/A
Composition 75 mg
Observations for this pharmaceutical form can be found on the lists:
PAHO Strategic Fund Medicine List
2.6. Antivirals
  • Others observations:
    Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times.
Powder for oral administration
Country lists
ATC N/A
Composition 20 mg/5 mL
Observations for this pharmaceutical form can be found on the lists:
Cuba
6.4 Antivirales
  • No observations
Capsule
Country lists
ATC N/A
Composition 45 mg (as phosphate)
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.3. Other antivirals
  • Others observations:
    Oseltamivir should be used only in compliance with the WHO treatment guidelines, i.e. (1) for treatment of patients with severe or progressive clinical illness with confirmed or suspected influenza pandemic (H1N1) 2009, (2) for the treatment of patients with confirmed or suspected but uncomplicated illness due to pandemic influenza virus infection who were in higher risk groups, most notably for pregnant women and children under 2 years of age.
Capsule
Country lists
ATC N/A
Composition 75 mg (as phosphate)
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.3. Other antivirals
  • Others observations:
    Oseltamivir should be used only in compliance with the WHO treatment guidelines, i.e. (1) for treatment of patients with severe or progressive clinical illness with confirmed or suspected influenza pandemic (H1N1) 2009, (2) for the treatment of patients with confirmed or suspected but uncomplicated illness due to pandemic influenza virus infection who were in higher risk groups, most notably for pregnant women and children under 2 years of age.
Cuba
6.4 Antivirales
  • No observations
Oral powder
Country lists
ATC N/A
Composition 12 mg/mL
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.3. Other antivirals
  • Others observations:
    Oseltamivir should be used only in compliance with the WHO treatment guidelines, i.e. (1) for treatment of patients with severe or progressive clinical illness with confirmed or suspected influenza pandemic (H1N1) 2009, (2) for the treatment of patients with confirmed or suspected but uncomplicated illness due to pandemic influenza virus infection who were in higher risk groups, most notably for pregnant women and children under 2 years of age.